A

Alnylam Pharmaceuticals

Develops RNAi-based therapies for genetic diseases

Associate Director - Statistical Programming

Quantitative Biology & BiostatisticsConfirmed live in the last 24 hours
Full-timeCambridge, MA, USA$181.1k - $244.9k

About the Job

Requirements

  • At least 10 years of industry SAS programming experience in pharmaceutical, biotech, or CRO settings, or equivalent.
  • Experience as a programming manager overseeing FTEs, Functional Service Providers, or vendors.
  • Experience leading programming teams supporting clinical trials, integrated program analyses, or electronic NDA or BLA submissions.
  • Experience constructing technical programming specifications and producing complex, validated SAS programs.
  • Demonstrated experience with CDISC standards, including SDTM, ADaM, and Define-XML.
  • Proficiency in statistical programming environments, processes, procedures, and roles.
  • Knowledge of SAS/Base, SAS/Macro, SAS/STAT, SAS/Graph, and SAS/SQL, including mastery of SAS/STAT procedures.
  • Hands-on experience with R programming for clinical trial data analysis, reporting, and regulatory submissions.
  • Knowledge of R packages and frameworks used in clinical development, Posit Workbench (RStudio Server), Posit Package Manager, and enterprise R environments.
  • Experience developing SOPs and standards or implementing programming best practices.
  • Experience overseeing vendors delivering quality programming support.
  • Bachelor’s degree in computer science, statistics, mathematics, or information sciences is required.
  • Written and oral communication and organizational skills are required.
  • Alignment with Alnylam’s Core Values: Commitment to People, Innovation and Discovery, Sense of Urgency, Open Culture, and Passion for Excellence.

Responsibilities

  • Provide technical and/or operational leadership in delivering high-quality and timely statistical programming for clinical studies, drug programs, and NDA submissions.
  • Work with Biostatistics to implement statistical analyses of clinical trial data, develop and validate CDISC ADaM specifications and datasets, and create tables, listings, and figures for regulatory, medical affairs, and market access needs.
  • Work with Data Management on cross-functional data review and the development and validation of CDISC SDTM specifications and datasets and Define packages; support Drug Safety with safety data review and reporting and Clinical Pharmacology with dataset creation and analyses as needed.
  • Manage internal and vendor statistical programming support and maintain collaboration and governance with preferred vendors.
  • Write SAS and R code to produce or validate tables, listings, figures, and analysis datasets for clinical studies or complex integrated submission analyses.
  • Plan, perform, and coordinate project work to ensure timely, quality delivery across multiple projects or a drug program.
  • Write specifications describing programming needs, including developing and maintaining complex ADaM specifications and reviewer guides.
  • Lead creation and validation of global macros or systems that streamline repetitive operations and improve programming efficiency as needed.
  • Provide input into or lead standardization efforts, including CRFs, query checks, standard statistical programs, and data presentations.
  • Lead development of programming processes consistent with industry best practices.
  • Review and provide expert input on DMPs, eCRF specifications, other clinical data management documents, statistical analysis plans, and related documents.
  • Partner with or oversee CROs or programming vendors in performing these tasks.

Desired Qualifications

  • A master’s degree in computer science, statistics, mathematics, or information sciences is preferred.
  • Experience with R programming, particularly data visualization and exploratory analysis, is strongly preferred.

About the Company

Alnylam Pharmaceuticals

Develops RNAi-based therapies for genetic diseases

Alnylam Pharmaceuticals develops RNA interference (RNAi) therapeutics to silence disease-causing genes, aiming to treat rare genetic disorders. Its products work by using RNA molecules that block gene expression, reducing the impact of specific genetic diseases. The company differentiates itself by concentrating on RNAi-based drugs for rare diseases and by building a pipeline through large clinical programs and strategic partnerships, such as commercialization deals in the Gulf States and collaborations with investors. Revenue comes from approved drug sales, licensing agreements, strategic collaborations, and related services like genetic testing and counseling. The company’s goal is to advance and commercialize RNAi therapies to improve outcomes for patients with genetic disorders, expanding its portfolio through partnerships and investments.

Company size
1,001-5,000
Company stage
IPO
Headquarters
Cambridge, MA
Founded
2002

Recently Posted Jobs

Explore more opportunities at Alnylam Pharmaceuticals

See more jobs